Novartis' Pluvicto expected to dominate prostate cancer radiopharmaceutical market
Novartis' Pluvicto is expected to dominate the market for radioligand therapies for prostate cancer, with revenue projections soaring to $4.3B by 2030. Read more here.
Cure Today9h
Challenges to Consider While Receiving Fotivda for Kidney Cancer
ESMO Congress, CURE® spoke with an expert about Fotivda and certain challenges patients may experience, such as side effects.
The American Journal of Managed Care10h
Pan-Immune-Inflammation–Based Nomogram Predicts OS, PFS in Epithelial Ovarian Cancer
Researchers developed a pan-immune-inflammation–based nomogram to accurately predict overall survival (OS) and ...
ENDPOINTS NEWS13h
John Car­roll on his can­cer di­ag­no­sis; #ES­MO's biggest sur­prise; Lykos' bad trip; Rate cuts, and more
Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every ...
El País in English19h
Kerstin Noëlle Vokinger: ‘New cancer therapies are being approved for patient groups not included in clinical trials’
Researchers from the universities of Zurich, Yale and Harvard reveal the differences between the characteristics of the ...